Skip to content

Research on the sensitivities of Sevoflurane among patients with Hepatopulmonary Syndrome

Research on the sensitivities of Sevoflurane among patients with Hepatopulmonary Syndrome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-15007560
Enrollment
Unknown
Registered
2015-12-11
Start date
2015-12-11
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatopulmonary Syndrome

Interventions

Case group: Patients with liver disease with HPS:No
Control group: Patients with liver disease without HPS:No
Healthy control group: Patients with normal liver function:No

Sponsors

Department of Anesthesia, Southwest Hospital, the Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) 40 to 70 years; (2) liver cirrhosis: according to the clinical manifestations, liver function tests, impact studies and pathological examination, the diagnosis of cirrhosis and Child-puge improved grading method was C grade (see Annex); (3) pulmonary microvascular dilation: Contrast enhanced echocardiography by chest showed the cloud and cloud shadow was found in the left ventricle and left atrium in 4 ~ 6 cardiac cycles after intravenous injection of 60 ~ 90µm normal saline; (4) arterial oxygenation function abnormality: standing position, resting blood gas analysis PO2=15 mmHg (greater than 64 year old elderly people>=20 mmHg); (5) preoperative assessment of ASA: I~III grade; (6) patients undergoing elective limb or abdominal surgery; (7) patients voluntarily participated in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Heart, lung, kidney disease; (2) forced expiratory volume in the first second [FEV1] or forced vital capacity [FVC]<70% forecast, or FEV1/FVC<0.70; (3) a metabolic disease; (4) more than 20% of the ideal body weight; (5) the treatment of an analgesic or a neuro - conditioning drug; (6) the researchers are not suitable for clinical trials because of other reasons.

Design outcomes

Primary

MeasureTime frame
Blood gas analysis;Hemodynamic parameters;respiratory function parameters;Depth of Anaesthesia;muscle relaxation depth;the dosage of anesthetic, muscle relaxation, analgesic and vasoactive drugs, the amount of fluid volume, blood loss, blood transfusion;postoperative pain score;postoperative adverse reactions;

Countries

China

Contacts

Public ContactKaizhi Lu
lukaizhi2010@163.com+86 13608380096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026